Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study

References

• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.1397531433515
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.058928448665
   PubMed Web of Science ®Google Scholar
• Huang YQ, Xu F, Yang JM, Huang B. Primary hepatic neuroendocrine carcinoma: clinical analysis of 11 cases. Hepatobiliary Pancreat Dis Int. 2010;9(1):44–48.20133228
   PubMed Web of Science ®Google Scholar
• Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–122. doi:10.1097/01.sla.0000129342.67174.6715213627
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi:10.1200/JCO.2007.15.437718565894
   PubMed Web of Science ®Google Scholar
• Wang HH, Liu ZC, Zhang G, et al. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol. 2020;12(9):1031–1043. doi:10.4251/wjgo.v12.i9.103133005296
   PubMed Web of Science ®Google Scholar
• Li YF, Zhang QQ, Wang WL. Clinicopathological characteristics and survival outcomes of primary hepatic neuroendocrine tumor: a Surveillance, Epidemiology, and End Results (SEER) Population-Based Study. Med Sci Monit. 2020;26:e923375. doi:10.12659/MSM.92337532651994
   PubMed Web of Science ®Google Scholar
• Song JE, Kim BS, Lee CH. Primary hepatic neuroendocrine tumor: a case report and literature review. World J Clin Cases. 2016;4(8):243–247. doi:10.12998/wjcc.v4.i8.24327574614
   PubMed Web of Science ®Google Scholar
• Camargo ÉS, Viveiros Mde M, Corrêa Neto IJ, Robles L, Rezende MB. Primary hepatic carcinoid tumor: case report and literature review. Einstein. 2014;12(4):505–508. doi:10.1590/S1679-45082014RC274525628206
   PubMedGoogle Scholar
• Fenoglio LM, Severini S, Ferrigno D, et al. Primary hepatic carcinoid: a case report and literature review. World J Gastroenterol. 2009;15(19):2418–2422. doi:10.3748/wjg.15.241819452590
   PubMed Web of Science ®Google Scholar
• Park CH, Chung JW, Jang SJ, et al. Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. J Gastroenterol Hepatol. 2012;27(8):1306–1311. doi:10.1111/j.1440-1746.2012.07117.x22414232
   PubMed Web of Science ®Google Scholar
• Parkash O, Ayub A, Naeem B, et al. Primary hepatic carcinoid tumor with poor outcome. J Coll Physicians Surg Pak. 2016;26(3):227–229.26975959
   PubMed Web of Science ®Google Scholar
• Chen RW, Qiu MJ, Chen Y, et al. Analysis of the clinicopathological features and prognostic factors of primary hepatic neuroendocrine tumors. Oncol Lett. 2018;15(6):8604–8610. doi:10.3892/ol.2018.841330065788
   PubMed Web of Science ®Google Scholar
• Qiu MJ, Chen YB, Bi NR, Yang SL, He XX, Xiong ZF. Comparative clinical analysis of gastroenteropancreatic neuroendocrine carcinomas with liver metastasis and primary hepatic neuroendocrine carcinomas. Dis Markers. 2018;2018:9191639. doi:10.1155/2018/919163930416612
   PubMed Web of Science ®Google Scholar
• Jiang S, Wu H, Fu R, et al. The outcome of primary hepatic carcinoid tumor: a Retrospective Study based on propensity score matched survival analysis. Front Oncol. 2021;11:609397. doi:10.3389/fonc.2021.60939733718162
   PubMed Web of Science ®Google Scholar
• Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40(4):313–318. doi:10.1093/jjco/hyp17320047862
   PubMed Web of Science ®Google Scholar
• Okumura Y, Kohashi K, Wang H, et al. Combined primary hepatic neuroendocrine carcinoma and hepatocellular carcinoma with aggressive biological behavior (adverse clinical course): a case report. Pathol Res Pract. 2017;213(10):1322–1326. doi:10.1016/j.prp.2017.06.00128647212
   PubMed Web of Science ®Google Scholar
• Li MX, Li QY, Xiao M, et al. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors. Hepatobiliary Pancreat Dis Int. 2019;18(6):538–545. doi:10.1016/j.hbpd.2019.03.00930981633
   PubMed Web of Science ®Google Scholar
• Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860. doi:10.1016/j.annonc.2020.03.30432272208
   PubMed Web of Science ®Google Scholar
• Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160. doi:10.1093/annonc/mds27622967994
   PubMed Web of Science ®Google Scholar
• Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956–2962. doi:10.1245/s10434-014-3725-324763982
   PubMed Web of Science ®Google Scholar
• Bongiovanni A, Riva N, Ricci M, et al. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Onco Targets Ther. 2015;8:3613–3619. doi:10.2147/OTT.S9197126664145
   PubMed Web of Science ®Google Scholar
• Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–2823. doi:10.1002/cncr.2872124771552
   PubMed Web of Science ®Google Scholar
• Freis P, Graillot E, Rousset P, et al. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep. 2017;7:40609. doi:10.1038/srep4060928074897
   PubMed Web of Science ®Google Scholar
• Walter T, Tougeron D, Baudin E, et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer. 2017;79:158–165. doi:10.1016/j.ejca.2017.04.00928501762
   PubMed Web of Science ®Google Scholar
• Shiba S, Morizane C, Hiraoka N, et al. Pancreatic neuroendocrine tumors: a single-center 20-year experience with 100 patients. Pancreatology. 2016;16(1):99–105. doi:10.1016/j.pan.2015.11.00126718527
   PubMed Web of Science ®Google Scholar
• Sobecki M, Mrouj K, Colinge J, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77(10):2722–2734. doi:10.1158/0008-5472.CAN-16-070728283655
   PubMed Web of Science ®Google Scholar
• Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117(20):4617–4622. doi:10.1002/cncr.2612421456005
   PubMed Web of Science ®Google Scholar
• Olsen IH, Sørensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Sci World J. 2012;2012:170496. doi:10.1100/2012/170496
   Web of Science ®Google Scholar
• Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105(9):1176–1181. doi:10.1111/cas.1247324975505
   PubMed Web of Science ®Google Scholar